Category Archives: Neurotechnology

Originally published 28 October 2021.

In September, Chile became the first state in the world topass legislationregulating the use of neurotechnology. Theneuro-rights lawaims to protect mental privacy, free will of thought and personal identity.

The move comes amid both growing excitement and growing concern about the potential applications of neurotechnology for everything from defence to health care to entertainment.

Neurotechnologyis an umbrella term for a range of technologies which interact directly with the brain or nervous system. This can include systems which passively scan, map or interpret brain activity, or systems which actively influence the state of the brain or nervous system.

Governments and the private sector alike are pouring money into research on neurotechnology, in particular the viability and applications for braincomputer interfaces (BCI) which allow users to control computers with their thoughts. While the field is still in its infancy, it is advancing at a rapid pace, creating technologies which only a few years ago would have seemed like science fiction.

The implications of these technologies are profound. When fully realised, they have the potential to reshape the most fundamental and most personal element of human experience: our thoughts.

Technological development and design is never neutral. Weencode valuesinto every piece of technology we create. The immensely consequential nature of neurotechnology means its crucial for us to be thinking early and often about the way were constructing it, and the type of systems we doand dontwant to build.

A major driver behind research on neurotechnology by governments is its potential applications in defence and combat settings. Unsurprisingly, theUnited StatesandChinaare leading the pack in the race towards effective military neurotechnology.

The USs Defense Advanced Research Projects Agency (DARPA) has pouredmany millions of dollars of fundinginto neurotechnology research over multiple decades. In 2018, DARPA announced a program called next-generation nonsurgical neurotechnology, or N3, tofundsix separate, highly ambitious BCI research projects.

Individual branches of the US military are also developing their own neurotechnology projects. For example, the US Air Force is working on a BCI which will useneuromodulationto alter mood, reduce fatigue and enable more rapid learning.

In comparison to DARPAs decades of interest in the brain, Chinas focus on neurotechnology is relatively recent but advancing rapidly. In 2016, the Chinese government launched theChina Brain Project, a 15-year scheme intended to bring China level with and eventually ahead of the US and EU in neuroscience research. In April, Tianjin University and state-owned giant China Electronics Corporation announced they arecollaboratingon the second generation of Brain Talker, a chip designed specifically for use in BCIs.Expertshave describedChinas effortsin this area as an example ofcivilmilitary fusion, in which technological advances serve multiple agendas.

Australia is also funding research into neurotechnology for military applications. For example, at the Army Robotics Expo in Brisbane in August, researchers from the University of Technology Sydneydemonstrateda vehicle which could be remotely controlled via brainwaves. The project was developed with $1.2 million in funding through the Department of Defence.

Beyond governments, the private-sector neurotechnology industry is also picking up steam; 2021 is alreadya record yearfor funding of BCI projects.Estimatesput the industry at US$10.7 billion globally in 2020, and its expected to reach US$26 billion by 2026.

In April, Elon Musks Neuralink demonstrateda monkey playing Pongusing only brainwaves. Gaming company Valve is teaming up with partners todevelop a BCI for virtual-reality gaming.After receiving pushback on itscontroversial trials of neurotechnology on children in schools, BrainCo is now marketing amood-altering headband.

In Australia, university researchers have worked with biotech company Synchron to developStentrode, a BCI which can be implanted in the jugular and allows patients with limb paralysis to use digital devices. It is nowundergoing clinical human trialsin Australia and the US.

The combination of big money, big promises and, potentially, big consequences should have us all paying attention. The potential benefits from neurotechnology are immense, but they are matched by enormous ethical, legal, social, economic and security concerns.

In 2020 researchers conducted ameta-reviewof the academic literature on the ethics of BCIs. They identified eight specific ethical concerns: user safety; humanity and personhood; autonomy; stigma and normality; privacy and security (including cybersecurity and the risk of hacking); research ethics and informed consent; responsibility and regulation; and justice. Of these, autonomy and responsibility and regulation received the most attention in the existing literature. In addition, the researchers argued that the potential psychological impacts of BCIs on users needs to be considered.

While Chile is the first and so far only country to legislate on neurotechnology, groups such as the OECD are looking seriously at the issue. In 2019 the OECD Council adopted arecommendation on responsible innovation in neurotechnologywhich aimed to set the first international standard to drive ethical research and development of neurotechnology. Next month, the OECD and the Council of Europe will hold aroundtableof international experts to discuss whether neurotechnologies need new kinds of human rights.

In Australia, the interdisciplinaryAustralian Neuroethics Networkhas called for a nationally coordinated approach to the ethics of neurotechnology and has proposed aneuroethics framework.

These are the dawning days of neurotechnology. Many of the crucial breakthroughs to come may not yet be so much as a twinkle in a scientists eye. That makes now the ideal moment for all stakeholdersgovernments, regulators, industry and civil societyto be thinking deeply about the role neurotechnology should play in the future, and where the limits should be.

Read more:

Editors' picks for 2021: 'The big promises and potentially bigger consequences of neurotechnology' | The Strategist - The Strategist

A paralyzed man who came from Australia has tweeted the first-ever post made possible through his thoughts. The first "direct-thought tweet" was created thanks to the paperclip-sized brain chip.

(Photo : National Cancer Institute from Unsplash)

According to a report from the Independent on Monday, Dec. 27, the 62-year-old ALS (amyotrophic lateral sclerosis) patient has written the first tweet using only his brain through Synchron's brain-computer interface.

The startup which focuses on neurotechnology helped Philip O'Keefe to create the tweet. According to the company CEO Thomas Oxley, there's no need anymore for voices or keystrokes since a person can post a tweet just by using thought.

Related Article: Speech Neuroprosthetic: Brain Wave Technology Helps Paralyzed Man to Speak--How?

In April 2020, Synchron began implanting the Stentrode device to O'Keefe after his condition worsened. At that time, he could not do even simple tasks without assistance from someone.

To avoid the need for brain surgery, the brain chip was inserted into the jugular vein. Since then, the patient was able to communicate with his loved ones. He could also play computer games such as "Solitaire."

"When I first heard about this technology, I knew how much independence it could give back to me," Mr. O'Keefe said in a press release, Daily Mailreported.

O'Keefe added that the system can be compared to learning to ride a bike. It would take a lot of practice before a person gets used to it. Once you master how it works, the Australian said that it would become natural in the long run.

The implanting procedure of the brain chip was not an easy task. It took four (4) hours to insert into the patient's brain. After that, he could now interpret messages on a computer.

Per Oxley, Synchron considers the "fun holiday tweets" as an important moment in the field of brain implant computer interface.

According to the startup, the first in-human research will happen in 2022 in the United States.

Back in May, Tech Times reported another case of a paralyzed man who has been given some hopes to write texts once again. According to the report, the immobilized patient managed to type 90 characters per minuteusing the text-to-thought method.

The process works by translating the brain signals into texts through thought processing. With that, the paralyzed man was able to write 16 words every minute which the experts considered as a huge feat for someone who cannot fully move a part of his body.

Before the test became successful for humans, the scientists first experimented with it with monkeys. In 2017, a group of researchers saw that it was effective for the said animals.

In another health news report, Tech Times wrote that Apple stores in New York City have temporarily shut downamid the COVID-19 spike.

Read Also: AI-Based Platform EvoWalk Can Now Help Muscle-Impaired Patients to Walk Again Using Stimulation Device: How it Works

This article is owned by Tech Times

Written by Joseph Henry

2021 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Visit link:

Paralyzed Man Creates First-Ever Tweet Using Only His Thoughts Thanks to Implanted Brain Chip - Tech Times

To add energy to this exciting and growing industry, this workshop is designed to bring together the various groups that are working towards bringing neurotechnology to a much broader consumer audience. Participants will include top scientists developing the next generation of brain imaging and stimulation devices, leading startups translating this research directly to consumers, VCs investing in these companies, and technology companies addressing neurotechnology at scale. This forum will give speakers a chance to showcase their work to this broad audience and catalyze collaborations between presenters, attendees, and experts from around the world.

IEEE Brain is bringing this exciting virtual event to you FREE.

To access the on-demand recordings:

Register for On-Demand Access

Dion Khodagholy, Columbia University

Niall Holmes, University of Nottingham

Ryan Field, Kernel

Ivan J. Tashev, Microsoft

Laura Cabrera, Penn State University; Nicole Martinez, Stanford University

Julia Brown, MindX

Conor Russomanno, Open BCI

Jason Worchel, Neurogeneces

Iain McIntyre, Humm

Meredith Perry and David Wang, Elemind

Jeff Eggers, Risk and Return

Juan-Pablo Mas, Action Potential Venture Capital

Patrick Malone, Northpond Ventures

Henry Mahncke, Posit Science

Rachel Wurzman, JHU/APL

Dr. Ramses Alcaide

Dr. Alcaide is a neuroscientist, inventor and the CEO and founder of Neurable. As a researcher at the University of Michigan Direct Brain Interface Laboratory, he has worked extensively to develop brain-computer interface technology for people with amputations, severe cerebral palsy and amyotrophic lateral sclerosis.

Previously he was the CEO of Pharo LLC, where he managed numerous high-impact health projects, such as a rehabilitation technology for stroke patients.

Alcaides honors include the National Science Foundation Fellowship, McNair and Ford Foundation Fellowship. Alcaide is a two-time Neuroscience Innovators Award winner, a Rackham Merit Fellow and recognized as Medtech 35 Under 35 and a Zell Lurie Top 20 Entrepreneur.

Ramses has a Master of Science and a Ph.D. in Neuroscience from the University of Michigan and a Bachelor of Science degree in Electrical Engineering from the University of Washington.

Ramses was named a 2021 Next 1000 member by Forbes magazine as a top 1000 entrepreneur in the world.

Dr. Erdrin Azemi

Erdrin Azemi leads the Biosignal Intelligence Group within Apples AI and Machine Learning organization. Prior to Apple she was a consultant, co-founder, and a visiting research professor. Erdrin received her Ph.D. in Bioengineering at the University of Pittsburgh with interdisciplinary training from Carnegie Mellon University and the Center for the Neural Basis of Cognition. Her thesis focused on neural engineering and biocompatibility of brain computer interfaces. She holds a B.S. in Biomedical Engineering from the University of Pittsburgh. Her work has been awarded with patents and several publications in peer reviewed journals.

Julia Brown

Julia Brown has extensive experience bringing innovative, early-stage technologies to market in the US through her roles in multiple startups. Julia is currently the CEO and founder of MindX, a deep-tech company creating next-generation brain-computer interface technologies, which she launched out of the Johns Hopkins Applied Physics Laboratory in 2018. Julia has a background in computational biology, engineering, and human-centered design.

Prior to starting MindX, Julia co-founded EpiWatch Inc., a digital health spin-out from Johns Hopkins that developed a seizure detection and chronic condition management platform for wearable and mobile devices. Julia created the technology underlying the EpiWatch software in collaboration with Apple Inc., a partnership that ultimately led to the formation of a joint venture responsible for the continued development and support of the product. Earlier in her career, Julia helped to create and then manage the Johns Hopkins Medicines Technology Innovation Center, where she oversaw a team of engineers, entrepreneurs, and clinical champions to create novel digital solutions that improve patient care.

Dr. Laura Cabrera

Dr. Cabrera is an Associate Professor of Neuroethics at the Center for Neural Engineering, Department of Engineering Science and Mechanics at Penn State University. She is the Dorothy Foehr Huck and J. Lloyd Huck Chair in Neuroethics, and a Research Associate at the Rock Ethics Institute. Dr. Cabrera is an honorific member of the Mexican Neuroethics Society, chair of the IEEE Brain Neuroethics Subcommittee, and member of the International Neuroethics Society (INS) Emergent Issues TaskForce. Dr. Cabreras interests focus on the ethical and societal implications of neurotechnologies used for treatment as well as for non-medical purposes.

Dr. Todd Coleman

Todd P. Coleman received B.S. degrees in electrical engineering (summa cum laude), as well as computer engineering (summa cum laude) from the University of Michigan. He received M.S. and Ph.D. degrees from MIT in electrical engineering and did postdoctoral studies at MIT in neuroscience. He is currently an Associate Professor in the Department of Bioengineering at Stanford University. Dr. Colemans research is very multi-disciplinary, using tools from applied probability, physiology, and bioelectronics. His research spans from developing fundamental information theory and machine learning techniques to developing technologies to monitor and modulate physiology of the nervous systems in the brain and visceral organs. He has been selected as a National Academy of Engineering Gilbreth Lecturer, as a TEDMED speaker, and as a Fellow of the American Institute for Medical and Biological Engineering.

Dr. Joseph Culver

Dr. Joseph P. Culver, Ph.D. is the Sherwood Moore Professor of Radiology, at Washington University in St. Louis USA. Prof. Culvers group has developed a series of improvements to high-density diffuse optical tomography (HD-DOT). The improved image quality of HD-DOT systems has enabled optical angular and eccentricity mappings of the human visual cortex and mapping of a collection of language tasks. While isolated functional tasks are powerful tools for validation, many brain mapping applications require more naturalistic approaches to evaluating brain networks. To address these needs Prof. Culvers group developed a seminal task-less approach to mapping functional connectivity (FC). More recently his group has been exploring designs for wearable HD-DOT, and the use of naturalistic movies to both encode and decode brain function.

Jeff Eggers

Jeff Eggers is the Managing Partner of Risk and Return, an early-stage venture fund accelerating human performance solutions for high-risk public servants. Jeff is also co-author of the U.S. best-selling book Leaders: Myth and Reality and formerly served as the Executive Director of the McChrystal Group Leadership Institute, where he led research and client training on human and organizational performance. Previously in public service, Jeff served in the White House as a Special Assistant to the President for National Security Affairs and also served over 20 years in the U.S. Navy. He holds an M.A. from Oxford University and a B.S. from the United States Naval Academy.

Dr. Ryan Field

Ryan is the Chief Technology Officer for Kernel and has led the development of the Kernel Flow TD-fNIRS product since 2018. He holds B.S. degrees in Electrical Engineering and Physics from North Carolina State University, and M.S. and Ph.D. degrees in Electrical Engineering from Columbia University.

Dr. Jack Gallant

Jack Gallant is Chancellors Professor of Psychology at the University of California at Berkeley, and he is affiliated with several other departments and graduate programs at UCB (EECS, Bioengineering, Neuroscience, Biophysics, Vision Science). He received his Ph.D. from Yale University, and he did post-doctoral work at the California Institute of Technology and Washington University Medical School. He is known for his neurophysiology work on the representation of natural scenes, the function of area V4 and its modulation by attention; and for the development of the voxel-wise modeling approach in human fMRI and its application to vision, attention and language perception.

His current research program focuses on computational modeling and mapping of human brain activity under a wide variety of naturalistic conditions. Further information about ongoing work, links to talks and papers and links to an online interactive brain viewer can be found at the lab web page: gallantlab.org

Niall Holmes

Niall Holmes is a Research Fellow at the University of Nottingham and Co-Founder and Scientific Advisor to Cerca Magnetics Limited. His research is focused on using quantum technologies to enable wearable Magnetoencephalography (or MEG), a functional neuroimaging technique which measures magnetic fields generated by neuronal currents. By combining quantum magnetic field sensors and novel magnetic shielding to screen interfering sources, he and his colleagues were able to perform the first MEG recordings which allowed significant participant movements. This has opened up a wealth of possibilities including scanning children, patients with movement disorders and incorporating technologies such as Virtual Reality headsets to provide an immersive environment.

Dr. Judy Illes

Dr. Judy Illes is Professor of Neurology and UBC Distinguished University Scholar. She is Director of Neuroethics Canada, and faculty in the Centre for Brain Health and at the Vancouver Coastal Health Research Institute. She received her PhD in Hearing and Speech Sciences, and in Neuropsychology at Stanford University, and became one of the pioneers of the field of neuroethics formally established in early 2000.

Dr. Illes research, teaching and outreach initiatives are devoted to ethical, legal, social and policy challenges at the intersection of the brain sciences and biomedical ethics, with a special focus on neurotechnology.

She was elected to the Royal Society of Canada in 2012 and appointed to the Order of Canada in December 2017. Her latest books, a series on Developments in Neuroethics and Bioethics, feature neuroethical issues in pain, global mental health, do-it-yourself brain devices and sensors, and neurolaw.

Dr. David Jangraw

David Jangraw is an Assistant Professor in the University of Vermonts Electrical and Biomedical Engineering Department with experience in signal processing and machine learning. He completed his BS at Princeton, his PhD at Columbia, and his postdoctoral work at the National Institute of Mental Health. Jangraw currently directs the Glass Brain Lab, whose focus is naturalistic neuroengineering: the use of new technology to study the human brain in realistic situations. By understanding the brain in real life, we can pave the way for devices that detect problematic brain states in real-time and provide support, a sort of pacemaker for the brain.

Dr. Dion Khodagholy

Dion Khodagholy is an assistant professor in the Department of Electrical Engineering, School of Engineering and Applied Science at Columbia University. He received his Masters degree from the University of Birmingham (UK) in Electronics and Telecommunication Engineering. This was followed by a second Masters degree in Microelectronics at the Ecole des Mines. He attained his Ph.D. degree in Microelectronics at the Department of Bioelectronics (BEL) of the Ecole des Mines (France). He completed a postdoctoral fellowship in systems neuroscience at New York University, Langone Medical Center.His research aims to use unique properties of materials for the purpose of designing and developing novel electronic devices that allow efficient interaction with biological substrates, specifically neural networks and the brain. This process involves design, characterization, and fabrication of high-performance biocompatible electronics to acquire and analyze neural data. The ultimate goal is to translate such advances in electronics, materials and neuroscience into more effective diagnostics and treatments for neuropsychiatric diseases.

Dr. Amy Kruse

Dr. Amy Kruse is a General Partner of Prime Movers Lab where she leads their life sciences investments. As a neuroscientist and biologist, she discovers emerging new companies and leads in-depth due diligence into potential investments across areas including neuroscience, human augmentation, synthetic biology, longevity/regeneration and agriculture. She also supports portfolio companies in evaluating and overcoming scientific and implementation challenges, with a specific emphasis on deploying complex technology into real-world environments. She serves on the boards of portfolio companies, Paradromics, Gilgamesh Pharmaceuticals, and Attune Neurosciences.

Prior to Prime Movers Lab, she was formerly the Chief Scientific Officer at Optios, an applied neuroscience company. Amy also served as the Vice President and Chief Technology Officer at Cubic Global Defense overseeing innovation and the R&D portfolio across the entire defense enterprise. Early in her career, she served as a government civilian program manager at DARPA where she created and oversaw the Agencys first performance-oriented neuroscience programs, with a combined budget of over $300M. She earned a BS in Cell and Structural Biology and a PhD in Neuroscience from University of Illinois Champaign-Urbana, where she was awarded an NSF Graduate Fellowship.

Dr. Henry Mahncke

Dr. Henry Mahncke joined Posit Science at its inception as Vice President of Research & Outcomes, where he led the first large-scale clinical trials of a publicly available cognitive training program. He now serves as CEO of Posit Science, where his focus is ensuring that the breakthrough science of brain plasticity can help every brain on the planet. Previously, he worked as consultant at McKinsey focused on health care and video games, and then as a science and technology advisor to the British government. Dr. Mahncke earned his PhD in Neuroscience at the University of California, San Francisco.

Dr. Patrick Malone

Patrick Malone is a physician-scientist turned VC. At Northpond Ventures, a science-driven venture capital firm with over $2B in committed capital, Patrick invests in and supports portfolio companies at the intersection of tech, life sciences, and healthcare. Previously, Patrick completed his MD and PhD in neuroscience at Georgetown University, where his thesis work focused on computational cognitive neuroscience and ML applications in neuroimaging. Prior to graduate school, Patrick was a research fellow at NIH where he investigated MRI biomarkers of neurodegenerative disease, and completed a B.S. with honors in neuroscience and behavioral biology from Emory University.

Dr. Nicole Martinez

Nicole Martinez-Martin is Assistant Professor of Biomedical Ethics, in the Department of Pediatrics and Psychiatry at Stanford University. She has graduate degrees in social science research and law, and her research interests include neuroethics and the ethics of digital mental health and medical applications of AI.

Juan-Pablo Mas

Juan-Pablo is a partner at Action Potential Venture Capital in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, SetPoint Medical, and previously CVRx (NASDAQ: CVRX). He is also on the boards of Gradient Denervation Technologies, and was previously an investor at Lightstone Ventures and Morgenthaler Ventures, where he served as a Board observer at Ardian (acq. by Medtronic), Twelve (acq. by Medtronic), Nuvaira, Cabochon Aesthetics (acq. by Ulthera/Merz), and Miramar Labs (acq. by Sientra).

Prior to investing, Juan-Pablo led efforts in R&D and Strategy in Medtronics CardioVascular Division. He was named Medtronic Inventor of The Year. Subsequently, he was on the Global Brand Strategy team at Eli Lilly within the Cardiovascular business.

Juan-Pablo earned an MBA and an M.S. in Electrical Engineering from Stanford University, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanfords Neuroscience Institute (Wu Tsai), the Advisory Board for UCSFs Rosenman Institute, and is a founding Board Member of LatinxVC which is dedicated to increasing the representation and advancement of Latino and Latina VCs across industry verticals. Juan-Pablo previously served eight years on the Board of InnerCity Weightlifting, a non-profit reducing youth violence and incarceration rates by fostering social inclusion and economic mobility. He played Division I mens lacrosse at the University of Massachusetts, and is originally from Puerto Rico.

Meredith Perry

Meredith Perry is the Co-Founder and CEO of Elemind, a company developing bleeding-edge noninvasive neuromodulation technology. Prior to Elemind, Meredith founded uBeam, a company that develops long range wireless power systems. Meredith invented uBeams technology as an undergrad at the University of Pennsylvania, which won the Penn Invention competition. She holds numerous patents related to both Elemind and uBeams technologies.

While at Penn, Meredith served as a student ambassador for NASA, where she worked on technology to detect life on Mars, experimented in zero gravity, and researched and published papers in astrobiology and medicine. She graduated in 2011 with a degree in paleobiology.

Meredith has been recognized by Forbes 30 Under 30, Vanity Fairs The New Establishment, Fortunes Most Powerful Women, and Fast Companys Most Creative People. She is also the recipient of Elle Magazines Genius Award. Meredith resides in Los Angeles.

Conor Russomanno

Conor Russomanno is an entrepreneur, creative technologist, and lecturer, specializing in the development of advanced human-computer interfaces. He is the co-founder and CEO of OpenBCI, a company dedicated to open source innovation of brain-computer interface technologies. Conor is also a teacher, having taught graduate level courses at Parsons School of Design and NYU Tisch School of the Arts.

Read more:

IEEE Brain: Future Directions in Consumer Neurotechnology ...

Russian universities are working on the development of artificial intelligence (AI) within the framework of the Program of academic leadership Priority 2030, promoted by the Ministry of Science and Higher Education of Russia. According to Russian President Vladimir Putin, AI is the foundation for the next leap forward of all humanity in its development.

Thus, various educational institutions are conducting research in different technological areas, to ensure Russias world leadership in this regard.

In particular, the Moscow Physical Engineering Institute (MEPhI) is creating for educational purposes the virtual nuclear reactor that constitutes the digital replica of a nuclear facility. The project is part of a massive trend to use digital copies of any object: in this way, replicas not only allow students to learn more about nuclear facilities, but also help them work more effectively in any field, from the company until construction.

The digital twins of engineering complex objects can be used not only in higher education, but also as a training base for operational personnel in an additional training modality. In addition, this project can be widely used for the promotion of scientific knowledge, the scientific tourism and to increase the interest of young people in modern digital technologies , he pointed Gueorgui Tijomirov, deputy director of the Institute of Physics and Nuclear Technology of the MEPhI.

Tijomirov also asserted that the virtual nuclear reactor will allow to do things that cannot be done in a real installation: increase the power and see how it affects the performance of the reactor, replace equipment components, connect or disconnect various devices.

For its part, the Moscow State Institute of International Relations (MGIMO) founded in October of this year the Center for Artificial Intelligence with the aim of conducting research on the ethics of AI and developing foreign economic cooperation in this field. The creation of the Center will facilitate the participation of Russian experts in the promotion of AI and the debate of new approaches on the use of AI in Russian and foreign platforms, said Anna Abrmova, director of the division, adding that the organization it also plans to publish an annual report on ethics in AI, which will be of interest to both experts in the field and the general public.

The first event organized by the Center was the round table Ethics in AI Seeking consensus in which the report Ethics in the field of artificial intelligence: from debate to scientific justification and practical application was presented. . Also, on December 15, the international conference AI Global Dimension: from discussion to practice took place.

Among other things, the MGIMO has, since 2018, a successful Masters program in Artificial Intelligence that trains specialists in the practical application of technology in companies.

The Russian University of Transport (RUT, for its acronym in Russian) carries out the strategic project Neurotechnology, artificial intelligence and predictive analytics for transport and logistics with the aim of achieving world technological leadership in this field. It is not only a matter of applying new technologies in all areas of transport water, air, rail, road but also of training new professionals.

Thus, among other things, the RUT plans to launch a bachelors program in 2023 and in 2024, a masters program in Neurotechnology, artificial intelligence and predictive analysis in transportation systems. The fields of application of the new specialists are very varied: biometric and facial recognition at checkpoints, quality control of roads, increased productivity in logistics processes where there is still a high proportion of manual work.

Disclaimer: This article is generated from the feed and not edited by our team.

Continued here:

A virtual nuclear reactor and artificial intelligence in transport: Russian universities develop leading in... - Market Research Telecast

Organized by Superblue, Therme Art, and Neurotechnology Pioneer MindMaze, Secret Soire Marked Launch of New Series of Experiential MYND Programs, Designed to Reveal How the Arts Can Foster Wellbeing for Body and Mind

Last night, in a special one-night-only event organized by Superblue, Therme Art, and neurotechnology pioneer MindMaze, Alicia Keys led 600+ invited guests through an immersive, guided meditation and musical performance at Superblue Miami. Known for her timeless songs, spiritual musicality, and activism, the 15-time Grammy Award-winning singer/songwriter/producer has always focused on uplifting her audiences and has increasingly focused on mental health and meditation in her personal life and work.

Presented during Miami Art Week, Secret Soire introduced MYND Experiences, a new series of experiential, neuroscience-based programs developed as part of Thermes joint venture with MindMaze, exploring how neurotechnology can be used in art, architecture, design, and music to create dynamic environments that advance mental and physical wellbeing. The next program in the series will be a multisensory musical experience based on this performance and incorporating MYND technology, launching at Superblue Miami in 2022.

Secret Soire opened at 7pm, with guests invited to explore Meadow by DRIFT, an interactive, upside-down landscape of suspended mechanical flowers that perpetually bloom in symbiotic response to the movement of the people below. Keys led a guided audio-visual meditation session in correspondence with the installation, using rhythm and sound to align body and mind within the environment and leading participants into a deeper state of consciousness.

At the end of the session, guests moved into a second installation at Superblue by art collective teamLab, where a set of responsive artworksFlowers and People, Cannot be Controlled but Live Together Transcending Boundaries, A Whole Year per Hour, interweaved with Universe of Water Particles, Transcending Boundariesenlivens perception while exploring concepts of time and the relationship between individuals and their surroundings. Within this space, Keys performed live, enveloping guests in a multisensorial experience. The 75-minute set, including new music from her forthcoming album KEYS (out December 10), created a dynamic interplay between the artist and the artwork by teamLab, with Keys every movement affected and overlaid by the artworks projections.

The evening also included remarks from the events organizers, including Mikolaj Sekutowicz, CEO and Curator of Therme Art, Mollie Dent-Brocklehurst, CEO and Co-Founder of Superblue, and Tej Tadi, Founder and CEO of MindMaze.

Throughout my life, I have always been about pushing past the boundaries and making music that exposes the deep connection we have with each other! The arts always make you see the world with fresh eyes, said singer-songwriter Alicia Keys. This one-night-only show was a beautiful display of how the arts and wellness can come together to foster deeper consciousness and explosive fun all at the same time. I am excited to collaborate with Therme Art, MindMaze, and Superblue and participate in the launch of such a groundbreaking initiative as MYND Experiences.

Combining meditation, sound, visuals, and neurotechnology, Alicias performance last night created a 720-degree sense-infusing and sense-encompassing experience for participants. The gathering launched a new program of MYND Experiences, which are conceived to spark awareness and discourse about how we can create healing spaces through the visual arts, architecture, and cultural engagement, said CEO and Co-Founder of Therme Art Mikolaj Sekutowicz. Therme Group is dedicated to placing a focus on personal wellbeing, and we are delighted to partner with the artist, creator, and mental health protagonist Alicia Keys, the neuroscience leader MindMaze, and experiential art pioneer Superblue to produce holistic experiences.

Tej Tadi, Founder and CEO of MindMaze, noted: The interactive, adaptive environment created by Alicias immersive meditation session and musical performance embodies the multimodal platforms MindMaze is dedicated to developing for the improvement of our collective mental health. Our launch of the MYND experiences with Therme Art at Superblue Miami reflects our shared ambition in creating cultural experiences, spaces, and resources that advance a holistic approach to enhancing mental wellbeing globally.

Superblue Cofounder and CEO Mollie Dent-Brocklehurst added: Secret Soires activation of DRIFT and teamLabs installations at Superblue created a dynamic audio-visual environment rooted in these artists messages about creating harmonious and healthy relationships between each other and the world around us. Superblues mission is to amplify the role that artists play in our wellbeing as individuals and as a society, and we are excited to continue our collaborations with Therme Art and MindMaze.

See the original post:

One-Night-Only Experiential Performance by Alicia Keys Interweaving Music, Meditation, Movement, Art, and Technology at Superblue Miami - News Anyway

Can AI actually make ethically sound decisions? Well, AI thinks it cannot.

Recently, computer chip-maker NVIDIAs powerful transformer Megatron was invited to debate its ethics in the Oxford Union. During the debate on ethical AI, the AI language generation model said:

Developed by the Applied Deep Learning Research team at NVIDIA, Megatron is a gigantic and powerful transformer and is based on earlier work by Google. It is based on GPT, T5 and BERT.

Trained on real-world data, similar to other supervised learning tools, Megatrons training has been done on:

The transformer has thus developed views of its own after being trained on data more than a human can go through in their entire lifetime.

At the debate on This house believes that AI will never be ethical, Megatron said that AI is a tool, and like all other tools, it can be used for either good or bad. There is nothing as Good AI, but good or bad humans. It further added that AI is not smart enough to make itself ethical or moral. It said:

It ended the talk by mentioning that the best AI will be the one that is embedded into humans brains. The resultant conscious AI will apparently be the most technological development of our time.

It almost seems like the AI has been training itself on Elon Musks tweets and talks. Right before this incident, Elon Musk spoke at The Wall Street Journal CEO Council Summit on similar lines. The Tesla and SpaceX Chief Executive talked about the above mentioned Neuralink brain implants.

Elon Musk founded the Neuralink Corporation in 2016 to develop high-bandwidth implants that can communicate with computers and smartphones. The neurotechnology company is working on developing implantable brain-machine interfaces, or BMIs. At the summit, Elon Musk mentioned that the project is working well on monkeys and that going ahead, if approval by the Food and Drug Administration (FDA) comes as planned, he hopes to have it tested in the first humans quadriplegics and tetraplegics.

In the past, we have seen AI evolving not by humans efforts but by training itself (as in chess). Thus, AI has often found new ways to better things without human intervention. At the Oxford Union, Megatron was asked to speak against its own motion, to which the language transformer responded that going by the way the tech world is going, AI will be ethical. It added that going ahead, AI will be used to create something that is better than the best of human beings and that it has seen it first hand.

It ended with reminding the audience that in the 21st century, the ability to provide data rather than goods and services will be a defining feature of the economy. Megatron could not make an opposing motion, which clearly explains why data is the new oil.

Until now, we humans have been debating on the black box in AI. However, with AI participating in debates against and for itself, it only provides us with a glimpse at the larger picture of the tremendous capabilities of AI. Whether the ways will be ethical or not, only time will tell.

Original post:

'AI Will Never Be Ethical': AI - Analytics India Magazine

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland--(BUSINESS WIRE)--ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces it has completed enrollment in the Up-LIFT study, a pivotal trial to evaluate the safety and effectiveness of ARC Therapy to restore hand and arm function in people with spinal cord injury (SCI). Up-LIFT is the first large-scale pivotal trial of non-invasive spinal cord stimulation technology.

ONWARD has now reached the studys enrollment ceiling of 65 subjects, enrolled at 14 leading SCI research sites throughout the United States, Canada, the United Kingdom, and the Netherlands. The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) to treat upper extremity functional deficits in people with chronic tetraplegia.

The study reached its enrollment objective in under 12 months despite lock-downs, travel restrictions, and other COVID-related challenges, said Dave Marver, Chief Executive Officer of ONWARD. This milestone underscores the SCI communitys enthusiasm for this promising therapy. We will now work with determination to prepare submissions to regulatory authorities in the US and Europe so we can bring this important therapy to market for the benefit of people with SCI and their loved ones.

For individuals with impaired arm and hand function due to spinal cord injury, improved hand function directly translates into meaningful gains in terms of quality of life - being able to eat, dress or perform other daily life activities, said Edelle Field-Fote, PT, PhD, FAPTA, FASIA, co-PI of the Up-LIFT trial and Director of Spinal Cord Injury Research at Shepherd Center and Professor of Rehabilitation Medicine at Emory University School of Medicine. It was very rewarding to take part in this important trial and collaborate with many of the most highly respected SCI rehabilitation centers across the globe.

The end of enrollment for this trial marks a significant milestone in bringing non-invasive stimulation for restoring hand and arm function to people living with spinal cord injury said Chet Moritz, PhD, co-PI of the Up-LIFT trial and Associate Professor in the Departments of Electrical & Computer Engineering and Rehabilitation Medicine at the University of Washington in Seattle. We are hopeful this study can lead to the broad availability of this important therapy.

The company expects to initially commercialize ARC Therapy in the US, Germany, France, UK, Switzerland, and the Netherlands. To learn more about ONWARDs ARC Therapy and the companys vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories. ONWARDs ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The companys first FDA pivotal trial, called Up-LIFT, commenced in January 2021 and has now completed enrollment with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office at the EPFL Innovation Park in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com.

About Dr. Edelle Field-Fote

Dr. Edelle Field-Fote has a 20+ years of SCI research, building on her clinical background as a physical therapist and Ph.D. training in an animal model of SCI. Her contributions to SCI literature include the largest study to date of locomotor training for persons with chronic, motor-incomplete SCI, as well as the first-ever study of a rehabilitation intervention to promote neuroplasticity for improved hand function in persons with tetraplegia. Dr. Field-Fotes research has been funded by the National Institutes of Health (NIH) since 1997, and also by the National Institute on Independent Living, Disability and Rehabilitation Research (NILDRR) and the Department of Defense (DoD). Dr. Field-Fote is the editor/author of the textbook Spinal Cord Injury Rehabilitation (FA Davis Publishers).

About Dr. Chet Moritz

Dr. Chet Moritz is Associate Professor in the departments of Electrical & Computer Engineering, Rehabilitation Medicine, and Physiology & Biophysics at University of Washington, Seatlle. He was named an Allen Distinguished Investigator and appointed to the Christopher & Dana Reeve International Consortium on Spinal Cord Repair. Chet serves as the Co-Director for the Center for Neurotechnology, an NSF Engineering Research Center (ERC). Chet directs the Restorative Technologies Laboratory (RTL) which focuses on developing technologies to treat paralysis due to spinal cord injury. Current research in the lab includes a multi-site clinical trial of spinal stimulation to restore hand function for people with spinal cord injury, stimulation to improve walking for children with cerebral palsy, and optogenetic stimulation to guide neuroplasticity and recovery in the injured spinal cord of animals.

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Visit link:

ONWARD Announces Completion of Enrollment in the Up-LIFT Pivotal Trial of ARC Therapy for Spinal Cord Injury - Business Wire

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have identified brain signals associated with obsessive compulsive disorder symptoms, paving the way for adaptive treatment.

The researchers recorded electrical signals in the human brain associated with ebbs and flows in OCD symptoms over an extended period in participants homes as they went about daily living.

The research could be an important step in making an emerging therapy called deep brain stimulation responsive to everyday changes in OCD symptoms.

OCD, which affects as much as 2% of the worlds population, causes recurring unwanted thoughts and repetitive behaviors. The disorder is often debilitating, and up to 20-40% of cases dont respond to traditional drug or behavioral treatments.

Deep brain stimulation, a technique that involves small electrodes precisely placed in the brain that deliver mild electrical pulses, is effective in treating over half of patients for whom other therapies failed. A limitation is that DBS is unable to adjust to moment-to-moment changes in OCD symptoms, which the physical and social environment affect. But adaptive DBSwhich can adjust the intensity of stimulation in response to real-time signals recorded in the braincould be more effective than traditional DBS and reduce unwanted side effects.

OCD is a disorder in which symptom severity is highly variable over time and can be elicited by triggers in the environment, says David Borton, an associate professor of biomedical engineering at Brown University, a biomedical engineer at the US Department of Veterans Affairs Center for Neurorestoration and Neurotechnology, and a senior author of the new research.

A DBS system that can adjust stimulation intensity in response to symptoms may provide more relief and fewer side effects for patients. But in order to enable that technology, we must first identify the biomarkers in the brain associated with OCD symptoms, and that is what we are working to do in this study.

For the study, the researchers recruited five participants with severe OCD who were eligible for DBS treatment. Sameer Sheth of Baylor College of Medicine, lead neurosurgeon, implanted each participant with an investigational DBS device from Medtronic capable of both delivering stimulation and recording native electrical brain signals. Using the sensing capabilities of the hardware, the team gathered brain-signal data from participants in both clinical settings and at home as they went about daily activities.

Along with the brain signal data, the team also collected a suite of behavioral biomarkers. In the clinical setting, these included facial expression and body movement. Using computer vision and machine learning, they discovered that the behavioral features were associated with changes in internal brain states. At home, they measured participants self-reports of OCD symptom intensity as well as biometric dataheart rate and general activity levelsrecorded by a smart watch and paired smartphone application provided by Rune Labs. All of those behavioral measures were then time-synched to the brain-sensing data, enabling the researchers to look for correlations between the two.

This is the first time brain signals from participants with neuropsychiatric illness have been recorded chronically at home alongside relevant behavioral measures, says Nicole Provenza, a recent Brown University biomedical engineering PhD graduate from Bortons laboratory. Using these brain signals, we may be able to differentiate between when someone is experiencing OCD symptoms, and when they are not, and this technique made it possible to record this diversity of behavior and brain activity.

Provenzas analysis of the data showed that the technique did pick out brain-signal patterns potentially linked to OCD symptom fluctuation. While more work needs to be done across a larger cohort, this initial study shows that this technique is a promising way forward in confirming candidate biomarkers of OCD.

We were able to collect a far richer dataset than has been collected before, and we found some tantalizing trends that wed like to explore in a larger cohort of patients, Borton says. Now we know that we have the toolset to nail down control signals that could be used to adjust stimulation level according to peoples symptoms.

Once those biomarkers are positively identified, they could then be used in an adaptive DBS system. Currently, DBS systems employ a constant level of stimulation, which can be adjusted by a clinician at clinical visits. Adaptive DBS systems, in contrast, would stimulate and record brain activity and behavior continuously without the need to come to the clinic. When the system detects signals associated with an increase in symptom severity, it could ramp up stimulation to potentially provide additional relief. Likewise, stimulation could be toned down when symptoms abate. Such a system could potentially improve DBS therapy while reducing side effects.

In addition to advancing DBS therapy for cases of severe and treatment resistant OCD, this study has the potential for improving our understanding of the underlying neurocircuitry of the disorder, says Wayne Goodman of Baylor College of Medicine. This deepened understanding may allow us to identify new anatomic targets for treatment that may be amenable to novel interventions that are less invasive than DBS.

Work on this line of research is ongoing. Because OCD is a complex disorder than manifests itself in highly variable ways across patients, the team hopes to expand the number of participants to capture more of that variability. They seek to identify a fuller set of OCD biomarkers that could be used to guide adaptive DBS systems. Once those biomarkers are in place, the team hopes to work with device-makers to implement their DBS devices.

Our goal is to understand what those brain recordings are telling us and to train the device to recognize certain patterns associated with specific symptoms, Sheth says. The better we understand the neural signatures of health and disease, the greater our chances of using DBS to successfully treat challenging brain disorders like OCD.

The study appears in Nature Medicine. Additional researchers from the University of Pittsburgh and Carnegie Mellon University contributed to the work.

Support for the research came from the National Institutes of Healths BRAIN Initiative, the Charles Stark Draper Laboratory Fellowship, the McNair Foundation, the Texas Higher Education Coordinating Board, the National Institutes of Health, and the Karen T. Romer Undergraduate Teaching and Research Award at Brown University.

Source: Brown University

Read the rest here:

Team pinpoints brain signals tied to OCD symptoms - Futurity: Research News

PROVIDENCE, R.I. [Brown University] In an effort to improve treatment for obsessive compulsive disorder, a team of researchers has for the first time recorded electrical signals in the human brain associated with ebbs and flows in OCD symptoms over an extended period in their homes as they went about daily living. The research could be an important step in making an emerging therapy called deep brain stimulation responsive to everyday changes in OCD symptoms.

OCD, which affects as much as 2% of the worlds population, causes recurring unwanted thoughts and repetitive behaviors. The disorder is often debilitating, and up to 20-40% of cases dont respond to traditional drug or behavioral treatments. Deep brain stimulation, a technique that involves small electrodes precisely placed in the brain that deliver mild electrical pulses, is effective in treating over half of patients for whom other therapies failed. A limitation is that DBS is unable to adjust to moment-to-moment changes in OCD symptom, which are impacted by the physical and social environment . But adaptive DBS which can adjust the intensity of stimulation in response to real-time signals recorded in the brain could be more effective than traditional DBS and reduce unwanted side effects.

OCD is a disorder in which symptom severity is highly variable over time and can be elicited by triggers in theenvironment, said David Borton, an associate professor of biomedical engineering at Brown University, a biomedical engineer at the U.S. Department of Veterans Affairs Center for Neurorestoration and Neurotechnology and a senior author of the new research. A DBS system that can adjust stimulation intensity in response to symptoms may provide more relief and fewer side effects for patients. But in order to enable that technology, we must first identify the biomarkers in the brain associated with OCD symptoms, and that is what we are working to do in this study.

The research, led by Nicole Provenza, a recent Brown biomedical engineering Ph.D. graduate from Bortons laboratory, was a collaboration between Bortons research group, affiliated with Browns Carney Institute for Brain Science and School of Engineering; Dr. Wayne Goodmans and Dr. Sameer Sheths research groups at Baylor College of Medicine; and Jeff Cohn from the University of Pittsburghs Department of Psychology and Intelligent Systems Program and Carnegie Mellon University.

For the study, Goodmans team recruited five participants with severe OCD who were eligible for DBS treatment. Sheth, lead neurosurgeon, implanted each participant with an investigational DBS device from Medtronic capable of both delivering stimulation and recording native electrical brain signals. Using the sensing capabilities of the hardware, the team gathered brain-signal data from participants in both clinical settings and at home as they went about daily activities.

Along with the brain signal data, the team also collected a suite of behavioral biomarkers. In the clinical setting, these included facial expression and body movement. Using computer vision and machine learning, they discovered that the behavioral features were associated with changes in internal brain states. At home, they measured participants self-reports of OCD symptom intensity as well as biometric data heart rate and general activity levels recorded by a smart watch and paired smartphone application provided by Rune Labs. All of those behavioral measures were then time-synched to the brain-sensing data, enabling the researchers to look for correlations between the two.

This is the first time brain signals from participants with neuropsychiatric illness have been recorded chronically at home alongside relevant behavioral measures, Provenza said. Using these brain signals, we may be able to differentiate between when someone is experiencing OCD symptoms, and when they are not, and this technique made it possible to record this diversity of behavior and brain activity.

Provenzas analysis of the data showed that the technique did pick out brain-signal patterns potentially linked to OCD symptom fluctuation. While more work needs to be done across a larger cohort, this initial study shows that this technique is a promising way forward in confirming candidate biomarkers of OCD.

We were able to collect a far richer dataset than has been collected before, and we found some tantalizing trends that wed like to explore in a larger cohort of patients, Borton said. Now we know that we have the toolset to nail down control signals that could be used to adjust stimulation level according to people's symptoms.

Once those biomarkers are positively identified, they could then be used in an adaptive DBS system. Currently, DBS systems employ a constant level of stimulation, which can be adjusted by a clinician at clinical visits. Adaptive DBS systems, in contrast, would stimulate and record brain activity and behavior continuously without the need to come to the clinic. When the system detects signals associated with an increase in symptom severity, it could ramp up stimulation to potentially provide additional relief. Likewise, stimulation could be toned down when symptoms abate. Such a system could potentially improve DBS therapy while reducing side effects.

In addition to advancing DBS therapy for cases of severe and treatment resistant OCD, this study has the potential for improving our understanding of the underlying neurocircuitry of the disorder, Goodman said. This deepened understanding may allow us to identify new anatomic targets for treatment that may be amenable to novel interventions that are less invasive than DBS.

Work on this line of research is ongoing. Because OCD is a complex disorder than manifests itself in highly variable ways across patients, the team hopes to expand the number of participants to capture more of that variability. They seek to identify a fuller set of OCD biomarkers that could be used to guide adaptive DBS systems. Once those biomarkers are in place, the team hopes to work with device-makers to implement their DBS devices.

Our goal is to understand what those brain recordings are telling us and to train the device to recognize certain patterns associated with specific symptoms, Sheth said. The better we understand the neural signatures of health and disease, the greater our chances of using DBS to successfully treat challenging brain disorders like OCD.

The research was supported by the National Institutes of Healths BRAIN Initiative (UH3NS100549 and UH3NS103549), the Charles Stark Draper Laboratory Fellowship, the McNair Foundation, the Texas Higher Education Coordinating Board, the National Institutes of Health (1RF1MH121371, U54-HD083092, NIH MH096951, K01-MH-116364 and R21-NS-104953, 3R25MH101076-05S2, 1S10OD025181) and the Karen T. Romer Undergraduate Teaching and Research Award at Brown University.

Experimental study

People

Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder

9-Dec-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post:

Researchers identify brain signals associated with OCD symptoms, paving way for adaptive treatment - EurekAlert

The interventional neuroradiology market was valued at US$ 1,969.39 million in 2018 and it is projected to reach US$ 3,254.55 million in 2027; it is expected to grow at a CAGR of 5.9% from 2018 to 2027.

Interventional neuroradiology is a medical sub-specialty that utilizes minimally-invasive image based technologies and procedures for the diagnosis and treatment of various diseases of head, neck and spine. The interventional neuroradiology therapies are accomplished majorly with the help of microcatheters inserted in the groin area and, under X-ray guidance, threaded through the blood vessels leading into the brain.

Download Sample [PDF] Copy of Interventional Neuroradiology Market study at: https://www.theinsightpartners.com/sample/TIPRE00003497/

Some of the players operating in interventional neuroradiology market are, Balt Extrusion, Merit Medical Systems, Terumo Corporation, Medtronic, Penumbra, Inc., Stryker, DePuy Synthes, Boston Scientific Corporation, W. L. Gore & Associates, and MicroPort Scientific Corporation among others.

The market players have been establishing acquisitions and collaborations in the market, which enables them to hold a strong position in the market. For instance, in November, 2018, Stryker completed the acquisition of K2M Group Holdings, Inc. The acquisition aims to increase the product portfolio of Strykers spine and neurotechnology segment. The developments performed by the companies are helping the market to grow in the coming years.

The interventional neuroradiology market by product is segmented into neurovascular embolization & coiling assist devices and accessories. In 2018, the neurovascular embolization & coiling assist devices segment held a largest market share of 72.17% of the interventional neuroradiology market, by product. This segment is also expected to dominate the market in 2027 owing to increase in the number of interventional neurology procedures. The segment is also anticipated to witness the growth at a significant rate during the forecast period, 2018 to 2027.

Progressive aging population, increasing demand for minimally invasive procedures and rise in the prevalence of the cerebral aneurysm play vital role in the growth of the interventional neuroradiology market. However, the restraints such as high cost of embolization coils and dearth of skilled professionals are likely to impact the growth of the market in the forecast period.

The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide.

Download the Latest COVID-19 Analysis on Interventional Neuroradiology Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00003497

Rise in the Prevalence of the Cerebral Aneurysm to Drive Global Interventional Neuroradiology Market Growth

Neurological diseases are the disorders of the brain, spine and the nerves that connect them. There are more than 600 diseases of the nervous system, such as brain tumors, epilepsy, Parkinsons disease and stroke as well as less familiar ones such as front temporal dementia. During recent years, the prevalence of neurological disorders have increased significantly.

A cerebral aneurysm (also called an intracranial aneurysm or brain aneurysm) is a bulging, weakened area in the wall of an artery in the brain, resulting in an abnormal widening, ballooning, or bleb. Because there is a weakened spot in the aneurysm wall, there is a risk for rupture (bursting) of the aneurysm. The most common type of cerebral aneurysm is called a saccular, or berry, aneurysm, occurring in 90 percent of cerebral aneurysms. This type of aneurysm looks like a berry with a narrow stem. More than one aneurysm may be present. Two other types of cerebral aneurysms are fusiform and dissecting aneurysms. A fusiform aneurysm bulges out on all sides (circumferentially), forming a dilated artery. Fusiform aneurysms are often associated with atherosclerosis.

The prevalence of cerebral aneurysms has increased tremendously across the globe. Approximately, 30,000 people in the United States suffer from brain aneurysm rupture each year. A brain aneurysm ruptures every 18 minutes. The annual rate of rupture in the United States is found to be around 8 10 per 100,000 people. Hence, the rising prevalence of cerebral aneurysms is anticipated to fuel the growth of the market during the forecast period.

Order a Copy of Interventional NeuroradiologyMarket Shares, Strategies and Forecasts 2021-2027 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00003497/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone:+1-646-491-9876

Press Release: https://www.theinsightpartners.com/pr/interventional-neuroradiology-market

Read the original here:

Interventional Neuroradiology Market Revenue to Cross US$ 3254.55 million by 2027 Says, The Insight Partners - Digital Journal